Dysplastic nevus laboratory findings: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
Aditya Ganti (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Dysplastic nevus}} | {{Dysplastic nevus}} | ||
{{CMG}} ; {{AE}} {{ADG}} | |||
==Overview== | |||
There are no [[Medical laboratory|laboratory]] findings associated with the [[diagnosis]] of melanoma. [[Serum]] [[lactate dehydrogenase|lactate dehydrogenase (LDH)]] may be elevated among [[Patient|patients]] with [[metastasis]]. | |||
==Laboratory Findings== | |||
*There are no [[Medical laboratory|laboratory]] findings associated with the [[diagnosis]] of melanoma. Measurement of [[serum]] [[Lactate dehydrogenase|LDH]] may be considered for follow-up among [[Patient|patients]] who have been [[Diagnosis|diagnosed]] with [[Cancer staging|stage]] IB-IV melanoma.<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | |||
===Lactate Dehydrogenase (LDH)=== | |||
*Once [[Metastasis|metastatic]] melanoma is [[Diagnosis|diagnosed]], serum [[lactate dehydrogenase|lactate dehydrogenase (LDH)]] may be helpful for follow-up.<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | |||
*For [[Patient|patients]] with [[Cancer staging|stage]] IB-IV melanoma, measurement of [[serum]] [[Lactate dehydrogenase|LDH]] may be considered every 6-12 months.<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | |||
==Diagnosis== | |||
The following [[algorithm]] illustrates the approach to [[Patient|patients]] with suspected melanoma.<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | |||
{{familytree/start |summary=Approach to melanoma}} | |||
{{familytree | | | | | | | | | A01 | | | | | | | | | | | | | A01=<div style="width: 7em; padding:1em;">Suspicious pigmented lesion</div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | B01 | | | | | | | | | | | | | B01=<div style="width: 7em; padding:1em;">Biopsy</div>}} | |||
{{familytree | | | | | | | |,|-|^|-|.| | | | | | | | | | | | }} | |||
{{familytree | | | | | | | |!| | | C01 | | | | | | | | | | | C01=<div style="width: 7em; padding:1em;">Inadequate</div>}} | |||
{{familytree | | | | | | | |!| | | |!| | | | | | | | | | | | }} | |||
{{familytree | | | | | | | |!| | | D01 | | | | | | | | | | | D01=<div style="width: 7em; padding:1em;">Rebiopsy</div>}} | |||
{{familytree | | | | | | | |`|-|v|-|'| | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | E01 | | | | | | | | | | | | | E01=<div style="width: 7em; padding:1em;">Melanoma confirmed</div>}} | |||
{{familytree | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|.| | }} | |||
{{familytree | F01 | | F02 | | F03 | | F04 | | F05 | | F06 | F01=<div style="width: 7em; padding:1em;">Breslow thickness</div>|F02=<div style="width: 7em; padding:1em;">Ulceration status</div>|F03=<div style="width: 7em; padding:1em;">Mitotic rate</div>|F04=<div style="width: 7em; padding:1em;">Depth and peripheral margin status</div>|F05=<div style="width: 7em; padding:1em;">Presence of satellitosis</div>|F06=<div style="width: 7em; padding:1em;">Clark level for lesions ≤ 1 mm</div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | G01 | | | | | | | | | | | | | G01=<div style="width: 7em; padding:1em;">Reassessment with complete physical examination, including neurological exam and lymph node assessment</div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | H01 | | | | | | | | | | | | | H01=<div style="width: 7em; padding:1em;">[[Melanoma staging|Staging]]</div>}} | |||
{{familytree/end}} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 05:25, 4 June 2019
|
Dysplastic nevus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dysplastic nevus laboratory findings On the Web |
|
American Roentgen Ray Society Images of Dysplastic nevus laboratory findings |
|
Risk calculators and risk factors for Dysplastic nevus laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
There are no laboratory findings associated with the diagnosis of melanoma. Serum lactate dehydrogenase (LDH) may be elevated among patients with metastasis.
Laboratory Findings
- There are no laboratory findings associated with the diagnosis of melanoma. Measurement of serum LDH may be considered for follow-up among patients who have been diagnosed with stage IB-IV melanoma.[1]
Lactate Dehydrogenase (LDH)
- Once metastatic melanoma is diagnosed, serum lactate dehydrogenase (LDH) may be helpful for follow-up.[1]
- For patients with stage IB-IV melanoma, measurement of serum LDH may be considered every 6-12 months.[1]
Diagnosis
The following algorithm illustrates the approach to patients with suspected melanoma.[1]
Suspicious pigmented lesion | |||||||||||||||||||||||||||||||||||||||||||||||
Biopsy | |||||||||||||||||||||||||||||||||||||||||||||||
Inadequate | |||||||||||||||||||||||||||||||||||||||||||||||
Rebiopsy | |||||||||||||||||||||||||||||||||||||||||||||||
Melanoma confirmed | |||||||||||||||||||||||||||||||||||||||||||||||
Breslow thickness | Ulceration status | Mitotic rate | Depth and peripheral margin status | Presence of satellitosis | Clark level for lesions ≤ 1 mm | ||||||||||||||||||||||||||||||||||||||||||
Reassessment with complete physical examination, including neurological exam and lymph node assessment | |||||||||||||||||||||||||||||||||||||||||||||||